Publication | Open Access

pMel17 is recognised by monoclonal antibodies NKI-beteb, HMB-45 and HMB-50 and by anti-melanoma CTL

Cancer ImmunosurveillanceAutoimmune DiseaseMedicineImmunologyTumor ImmunityPathologyImmune SurveillanceAutoimmunityImmune Checkpoint InhibitorAnti-melanoma CtlImmunotherapyMonoclonal Antibodies Nki-betebTumor Microenvironment